AstraZeneca (AZN.L) News
Track canonical SquawkNews coverage tagged to AZN.L, AstraZeneca. This hub brings together deduplicated headlines about london stock exchange, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BRIEF — AstraZeneca's Efzimfotase alfa Granted Priority Review In U.S.
Sept 18 (Reuters) — AstraZeneca PLC: Astrazeneca: Efzimfotase Alfa Granted Priority Review In Us As Treatment For Patients With Hypophosphatasia Aged 2 Years And Older Astrazeneca - Fda Decision On Efzimfotase Alfa Expec
REGULATION | Sep 18, 2026, 06:22 AM UTC
H
AstraZeneca: Datroway Approved in EU
AstraZeneca's Datroway approved in EU for metastatic TNBC
EQUITY | Jul 31, 2026, 08:55 AM UTC
L
Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder
Omeros gains as AstraZeneca's Ultomiris fails in rare blood disorder
EQUITY | Jul 27, 2026, 04:05 PM UTC
L
AZN ASTRAZENECA 2Q CORE EPS $2.63, EST. $2.48
AZN ASTRAZENECA 2Q CORE EPS $2.63, EST. $2.48
EQUITY | Jul 27, 2026, 09:20 AM UTC
H
UK Shares Rise as Investors Weigh Middle East Tensions; BP Gains
() -- London's FTSE 100 rose 0.20% on Tuesday as investors assessed renewed US pressure on Iran alongside corporate earnings updates and fresh UK economic data. The US threatened to reinstitute a naval blockade of Irania
EARNINGS | Jul 14, 2026, 03:46 PM UTC
H
AstraZeneca Shares Slide After Heart Drug Trial Misses Primary Endpoint
() -- AstraZeneca's (AZN.L, AZN.ST) shares fell sharply on Thursday morning after the British drugmaker disclosed that a late-stage clinical trial for its heart disease drug candidate Wainua failed to meet its main goals
GEOPOLITICS | Jul 09, 2026, 09:08 AM UTC